Herbert B. Newton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Herbert B. Newton has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Eric C. Bourekas
Depatments of Neurology and Neurosurgery, The Ohio State University Wexner Medical Center and James Cancer Hospital and Solove Research Institute, Columbus, OH, United States
5 shared publicationsH. Wayne Slone
Department of Radiology, The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH, United States
4 shared publications- Mark G. Malkin
Neuro-Oncology Program at Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond, VA, United States
3 shared publications - Ekokobe Fonkem
Department of Neurology, Division of Neuro-Oncology, Barrow Neurological Institute, Phoenix, AZ, United States
2 shared publications Nina A. Paleologos
Division of Neuro-Oncology and Department of Neurology, Advocate Health Care, Chicago IL, United States
2 shared publicationsRamya Tadipatri
Department of Neurology, Division of Neuro-Oncology, Barrow Neurological Institute, Phoenix, AZ, United States
2 shared publications
Latest Publications
- 26 August 2022
- Published by Elsevier
- p. 25-37
Overview of pathology and treatment of metastatic brain tumors
- 26 August 2022
- Published by Elsevier
- p. 25-37
Overview of pathology and treatment of metastatic brain tumors
- 26 August 2022
- Published by Elsevier
- p. 59-63
Overview of pathology and treatment of intramedullary spinal cord metastases
- 26 August 2022
- Published by Elsevier
- p. 59-63
Overview of pathology and treatment of intramedullary spinal cord metastases
- 26 August 2022
- Published by Elsevier
- p. 727-737
Chordomas and other skull base tumours
- 26 August 2022
- Published by Elsevier
- p. 473-490
Imaging of brain tumours in animal models of central nervous system cancer
- 26 August 2022
- Published by Elsevier
- p. 473-490
Imaging of brain tumours in animal models of central nervous system cancer
- 26 August 2022
- Published by Elsevier
- p. 547-556
Imaging of oligodendrogliomas
- 26 August 2022
- Published by Elsevier
- p. 767-773
Papillary glioneuronal tumours
- 26 August 2022
- Published by Elsevier
- p. 557-570
Primary central nervous system lymphoma
- 18 March 2022
- Published by Elsevier
- p. 635-646
Supportive care
- 25 January 2021
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 87 (5) , 599-611
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies
Purpose Given clinical activity of AR-42, an oral histone deacetylase inhibitor, in hematologic malignancies and preclinical activity in solid tumors, this phase 1 trial investigated the safety and tolerability of AR-42 in patients with advanced solid tumors, including neurofibromatosis type 2-associated meningiomas and schwannomas (NF2). The primary objective was to define the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs). Secondary objectives included determining pharmacokinetics and clinical activity. Methods This phase I trial was an open-label, single-center, dose-escalation study of single-agent AR-42 in primary central nervous system and advanced solid tumors. The study followed a 3 + 3 design with an expansion cohort at the MTD. Results Seventeen patients were enrolled with NF2 (n = 5), urothelial carcinoma (n = 3), breast cancer (n = 2), non-NF2-related meningioma (n = 2), carcinoma of unknown primary (n = 2), small cell lung cancer (n = 1), Sertoli cell carcinoma (n = 1), and uveal melanoma (n = 1). The recommended phase II dose is 60 mg three times weekly, for 3 weeks of a 28-day cycle. DLTs included grade 3 thrombocytopenia and grade 4 psychosis. The most common treatment-related adverse events were cytopenias, fatigue, and nausea. The best response was stable disease in 53% of patients (95% CI 26.6–78.7). Median progression-free survival (PFS) was 3.6 months (95% CI 1.2–9.1). Among evaluable patients with NF2 or meningioma (n = 5), median PFS was 9.1 months (95% CI 1.9–not reached). Conclusion Single-agent AR-42 is safe and well tolerated. Further studies may consider AR-42 in a larger cohort of patients with NF2 or in combination with other agents in advanced solid tumors. Trial registration NCT01129193, registered 5/24/2010.
- 25 January 2021
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 87 (5) , 599-611
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies
Purpose Given clinical activity of AR-42, an oral histone deacetylase inhibitor, in hematologic malignancies and preclinical activity in solid tumors, this phase 1 trial investigated the safety and tolerability of AR-42 in patients with advanced solid tumors, including neurofibromatosis type 2-associated meningiomas and schwannomas (NF2). The primary objective was to define the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs). Secondary objectives included determining pharmacokinetics and clinical activity. Methods This phase I trial was an open-label, single-center, dose-escalation study of single-agent AR-42 in primary central nervous system and advanced solid tumors. The study followed a 3 + 3 design with an expansion cohort at the MTD. Results Seventeen patients were enrolled with NF2 (n = 5), urothelial carcinoma (n = 3), breast cancer (n = 2), non-NF2-related meningioma (n = 2), carcinoma of unknown primary (n = 2), small cell lung cancer (n = 1), Sertoli cell carcinoma (n = 1), and uveal melanoma (n = 1). The recommended phase II dose is 60 mg three times weekly, for 3 weeks of a 28-day cycle. DLTs included grade 3 thrombocytopenia and grade 4 psychosis. The most common treatment-related adverse events were cytopenias, fatigue, and nausea. The best response was stable disease in 53% of patients (95% CI 26.6–78.7). Median progression-free survival (PFS) was 3.6 months (95% CI 1.2–9.1). Among evaluable patients with NF2 or meningioma (n = 5), median PFS was 9.1 months (95% CI 1.9–not reached). Conclusion Single-agent AR-42 is safe and well tolerated. Further studies may consider AR-42 in a larger cohort of patients with NF2 or in combination with other agents in advanced solid tumors. Trial registration NCT01129193, registered 5/24/2010.
- 1 January 2016
- Published by Elsevier
- p. 603-611
Chordomas and Other Skull Base Tumors